BioCentury
ARTICLE | Emerging Company Profile

Autifony: Sense and sensitivity

Autifony aims to improve auditory processing, prevent persistent hearing damage

June 17, 2013 7:00 AM UTC

Autifony Therapeutics Ltd. is developing compounds for hearing loss and tinnitus that modulate potassium channel Kv3, a target on inhibitory receptors of the CNS that may affect central auditory processing of speech and other sounds.

Age- or noise-related hearing loss may occur as a result of either cochlear damage that reduces signal transduction to the brain or deterioration of central auditory processing and cognitive decline that hinder interpretation of the remaining signal...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article